Anal Fissure Treatment Market is estimated to grow at a 8.20% CAGR and is expected to reach USD 2,526.5 Million by 2030
The Anal Fissure Treatment Market is estimated to grow at a 8.20% CAGR and is expected to reach USD 2,526.5 Million by 2030. The linear tear between the distal anal canal and mucosal lining is called the anal fissure. One of the common symptoms of this problem is the severe pain caused during the bowel movement. This pain can cause for several minutes and lasts up to a few hours. Some of the indications for surgical treatment of anal fissure are constipation, increase in the time needed for wound healing, excruciating anal pain, diarrhea, constipation, etc. This problem is generally caused by irregular food habits, fast food consumption, and old age.
The above are the major drivers that are promoting the growth of the Anal Fissure Treatment Market. Due to this, several companies are providing solutions and treatments for anal fissures. It is estimated that the Americas will hold the largest market share in the Anal Fissure Treatment Market. With substantial growth and technological advancements, the market will grow at a gradual rate.
The spread of the COVID-19 disease caused a huge disruption in the economy, healthcare, business, and other sectors. The Anal Fissure Treatment Market was highly affected by the COVID-19. The increase in the spread shifted the healthcare sector to the focus on constricting the spread of the disease. Along with that, the cases of anal fissure pain treatment and surgeries also decreased. The unavailability of necessary equipment also delayed the treatments. However, the removal of lockdown and development of vaccines will lead to steady and gradual growth of the market.
Anal Fissure Treatment Market Revenue, by Treatment, 2017 (USD Million)
Sources: MRFR Analysis
The major market drivers of the Anal Fissure Treatment Market are the increasing adoption of unhealthy lifestyles and fast food consumption. Also, childbirth trauma among women is a major driver of the Anal Fissure Treatment Market. Furthermore, the developing methods for chronic anal fissure treatment will also boost the market growth.
Major restraints for the Anal Fissure Treatment Market are the expiration of the patents of r the potential drugs and lack of awareness among people. Along with that, the lack of proper infrastructure for anal fissure pain treatment will reduce the market growth in the forecast period.
Several opportunities are projected to provide a significant boost for the Anal Fissure Treatment Market. The growing use of “Over-The- Counter-Drugs” for treatment will have a significant impact. Also, the technological advancements in the treatment for anal fissure growing awareness will enhance the market.
The growing development of other alternative drugs for chronic anal fissure treatment will be a major challenge. Also, the risks related to the surgery and the absence of a significant reimbursement policy will hinder the growth of the Anal Fissure Treatment Market.
The Compound Annual Growth Rate of the Anal Fissure Treatment Market is estimated to reach up to 7.6%. According to MRFR analysis, the value of the Anal Fissure Treatment Market will boost and reach up to USD 2,526.6 Million by the forecast period. The various developments and growing awareness for the treatment for anal fissure will lead to substantial growth.
Value Chain Analysis
The growing cases of a sedentary lifestyle and growing fast food will drive the market. Along with that, the development in the healthcare sector chronic anal fissure treatment will also strengthen the value chain of the market. Thus, the Anal Fissure Treatment Market will have a steady growth.
Anal Fissure Treatment Global Market Share, by Region, 2017 (%)
Sources: MRFR Analysis
The Anal Fissure Treatment Global Market segment is divided into rote of administration, type, and end-user. On the basis of type, the Anal Fissure Treatment Market is divided into surgery and medication. The medication is again segmented into laxatives, calcium channel blocking drugs, nitroglycerin, stool softeners, steroids, botulinum toxin, and anesthetics.
On the basis of Route of Administration, the Anal Fissure Treatment Global Market is segmented into topical and oral.
On the basis of end-user, the Anal Fissure Treatment Market is further fragmented into academic and research institutes, clinics, and hospitals. The growing cases of diarrhea, Cohn's disease, and constipation among the patients will enhance the market growth.
The Anal Fissure Treatment Industry on the basis of region is divided into Europe, Americas, Asia-Pacific, and the Middle East and Africa. It is valuated that the Americas will have the largest share in the market. Thus, the market value is anticipated to touch up to USD 1000.6 Million by the year 2023. Due to the growing cases of several diseases such as constipation, Crohn’s disease, childbirth trauma, in the major countries such as the US and Canada, the demand for chronic anal fissure treatment is rising simultaneously.
Furthermore, the European region will have the second-largest share in chronic anal fissure treatment. Other than the rising fast-food consumption, other diseases such as chronic constipation, diarrhea, and the rising population of the older generation will enhance the market growth.
Along with that, the increasing presence of several biotech and pharmaceutical companies in the Asia-Pacific region will cause major growth. Lastly, the Middle East and Africa will have the least growth. It is due to the increasing problems related to health, poor diet among the population. However, with the growing awareness, about treatments for chronic anal fissure treatment, this region will have a gradual growth.
The key players in the Anal Fissure Treatment Global Market play a major role in the development and market growth. The market players use different strategies such as collaboration, new ventures, mergers, acquisitions, product launches, etc.
Some of the key players in the Anal Fissure Treatment Market are as follows.
Abbott Laboratories, GlaxoSmithKline Plc, Valeant Pharmaceuticals, Eisai Co. Ltd. Taro Pharmaceutical Industries Ltd. Cook, Pfizer Inc. AstraZeneca, Bayer AG, Allergan Inc., Novasep, Geri-care Pharmaceuticals, healthy Life Pharma, Taj Pharmaceuticals, Troikaa Pharmaceuticals, PurduePharma, SRS Pharmaceuticals, Cigna, and others.
No recent development was found.
The report overview of the Anal Fissure Treatment Market is as follows.
Report Score and Segmentation
The report score highlights the market value, drivers, opportunities, and growth during the forecast period. It also gives information about the strategies used by the key players to boost their business. The information provided in this report is gathered from secondary and primary sources.
|Market Size||USD 4477.94 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Treatment Type, Route of Administration, End User and Region|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Pfizer Inc., Teva Pharmaceutical Industries Ltd, GlaxoSmithKline Plc, Cook, Cigna, Eisai Co. Ltd, Abbott Laboratories, Bayer AG, AstraZeneca, Allergan Inc., Valeant Pharmaceuticals International Inc., and Taro Pharmaceutical Industries Ltd|
|Key Market Opportunities||Joint ventures, strategic alliances, mergers and acquisitions, new product developments|
|Key Market Drivers||
Anal fissure treatment market projected to grow at approximately 8.20% CAGR during the assessment period (2020-2030).
The valuation of the global anal fissure treatment market is estimated to increase to USD 4477.94 MN by the end of 2030.
Advances in technology and the availability of various treatment options are major tailwinds pushing the growth of the global anal fissure treatment market.
North America holds the largest share in the global anal fissure treatment market, followed by Europe and the Asia Pacific, respectively.
Abbott Laboratories (U.S.), AstraZeneca (U.K.), Pfizer Inc. (U.S.), Eisai Co. Ltd. (Japan), GlaxoSmithKline Plc (U.K.), Cigna (U.S.), Taro Pharmaceutical Industries Ltd. (Israel), Bayer AG (Germany), Allergan Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Valeant Pharmaceuticals International Inc. (Canada), and Cook (U.S.), are some of the top players operating in the global anal fissure treatment market.